Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Description

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Conditions

Previously Treated Non-Small Cell Lung Cancer

Study Overview

Study Details

Study overview

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Condition
Previously Treated Non-Small Cell Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Birmingham

Veterans Administration Medical Center - Birmingham, Birmingham, Alabama, United States, 35233

Mobile

University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States, 36688

Anchorage

Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States, 99508

Anchorage

Anchorage Oncology Centre, Anchorage, Alaska, United States, 99508

Anchorage

Katmai Oncology Group, Anchorage, Alaska, United States, 99508

Anchorage

Providence Alaska Medical Center, Anchorage, Alaska, United States, 99508

Fairbanks

Fairbanks Memorial Hospital, Fairbanks, Alaska, United States, 99701

Goodyear

CTCA at Western Regional Medical Center, Goodyear, Arizona, United States, 85338

Jonesboro

Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States, 72401

Little Rock

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States, 72205

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    SWOG Cancer Research Network,

    Hossein Borghaei, STUDY_CHAIR, SWOG Cancer Research Network

    Study Record Dates

    2029-01-28